春雨直播app

"Cell therapy," which uses cells as medicine, is currently attracting significant attention. Cells are the smallest units that make up our bodies; each one is a living entity that carries genetic information, produces various proteins, and generates energy. For this reason, they are also referred to as "living drugs." The concept of cell therapy itself has been established for a long time, with examples including blood transfusions to replenish blood cell components and bone marrow transplants for blood cancers such as leukemia. However, the immune cell therapies that have emerged in recent years are characterized by the fact that cells are artificially processed outside the body to improve them for use as medicine. In particular, Chimeric Antigen Receptor (CAR) T-cell therapy has shown high response rates for blood cancers that were previously difficult to treat, bringing about a paradigm shift in treatment strategies.

I am currently conducting research and development on cell processing technologies for use in treatment, including the aforementioned CAR-T cell therapy. The most distinct characteristic of cell therapy compared to existing therapeutic drugs is that the cells circulate through the body to find lesions—such as cancer tissue—and then proliferate on their own, theoretically continuing to exert their effect until the target is eliminated. T cells, in particular, have a long lifespan among immune cells; in successful treatment cases, it has been confirmed that infused CAR-T cells can persist in the body for up to 10 years.

Furthermore, immune cell therapy is expanding its scope to diseases other than cancer. For example, in autoimmune diseases such as systemic lupus erythematosus—where immune cells recognize and attack the body's own cells—effective therapeutic results have been obtained using CAR-T cells capable of attacking B cells. The immune system originally has the role of continuously monitoring the body and maintaining its homeostasis. In that sense, it stands to reason that it would have broad applicability to chronically progressing diseases. Moreover, the true strength of the immune surveillance system should be demonstrated in the phase of prevention—preventing diseases from manifesting in the first place—with vaccines against infectious diseases being the ultimate success story. Regarding cancer, various studies have proven that it develops as a result of evading immune surveillance. I believe the ultimate goal may be to establish preventive immunotherapy that artificially enhances this surveillance capability, for example, in high-risk individuals.